Category: abrocitinib

Pfizer gets first approval, in UK, for Xeljanz follow-up Cibinqo

September 9, 2021 Auto Bot 0

Pfizer has claimed its first regulatory approval worldwide for Cibinqo, its JAK inhibitor for atopic dermatitis, from the UK’s Medicines and Healthcare products Regulatory Agency […]

Pfizer Reports Results of Abrocitinib in P-III JADE DARE Study to Treat Atopic Dermatitis

August 30, 2021 Auto Bot 0

Shots: The head-to-head P-III JADE DARE study involves assessing the efficacy of Abrocitinib (200mg, qd, PO) vs dupilumab (300mg, SC, q2w followed by 600mg induction […]

Pfizer Reports Results of Abrocitinib in Fifth P-lll JADE REGIMEN Across Different Dosing Regimens

November 12, 2020 Auto Bot 0

Shots: The P-lll JADE REGIMEN study involves assessing of Abrocitinib (100/ 200mg) vs PBO in 1233 patients aged ≥ 12 yrs. in a ratio (1:1:1) […]

FDA sets April verdict for Pfizer’s “underestimated” atopic dermatitis drug

October 28, 2020 Auto Bot 0

Pfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in atopic dermatitis, a drug that CEO Albert […]